

# Molecular epidemiology of carbapenem resistance in *Acinetobacter baumannii* isolates in Shahid Mohammadi Hospital, Bandar Abbas, Iran

Shahin Najar Peerayeh<sup>1</sup> Afsaneh Karmostaji<sup>2</sup> Maryam Ansari<sup>3</sup> Sedigheh Javadpour<sup>4</sup> Parivash Davoodian<sup>5</sup>  
Nahid Moradi<sup>6</sup> Mahshid Vahdani<sup>3</sup>

Associate Professor Department of Medical Bacteriology<sup>1</sup>, Tarbiat Modares University, Tehran, Iran. Assistant Professor Department of Medical Bacteriology<sup>2</sup>, MSc of Molecular Biology<sup>3</sup>, Associate Professor Department of Medical Bacteriology<sup>4</sup>, Assistant Professor Department of Infectious Disease<sup>5</sup>, MSc of Bacteriology<sup>6</sup>, Infectious & Tropical Diseases Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

(Received 22 Dec, 2013

Accepted 18 May, 2014)

## Original Article

### Abstract

**Introduction:** *Acinetobacter baumannii* is a major cause of nosocomial infections which affect mainly disabled patients in intensive care units. The bacteria may acquire resistance to antibiotics and hence can seriously endanger antibiotic therapy. The most important problem facing treatment of *A. baumannii* is increasing reports of resistance to a wide range of antibiotics, including carbapenems, as the treatment of choice for this bacterial infection. Oxacillinase-type carbapenemases belonging to Class D beta-lactamases (OXA-type) are among the main mechanisms of reasons for resistance to carbapenems. The present study aimed to evaluate the patterns of antibiotic resistance and the prevalence of carbapenemase genes of oxacillinases in clinical isolates of *A. baumannii* in a hospital in Bandar Abbas, Iran.

**Methods:** A total of 69 isolates of *Acinetobacter* were collected within two years from different samples of patients' bodies in the Shahid Mohammadi Hospital of Bandar Abbas. The isolates genus was identified using biochemical methods and *A. baumannii* species using PCR. Antibiotic resistance to imipenem and meropenem was identified through disk diffusion method. OXA-type carbapenem resistance genes were identified by multiplex PCR. The data were statistically analyzed through the chi-square test using SPSS 17, and the graphs were plotted using Excel.

**Results:** Out of 69 *Acinetobacter* isolates, 57 (82.6%) had bla<sub>OXA-51</sub> gene and were identified as *A. baumannii*. Antibiogram showed a significant resistance to beta-lactams and other antibiotics studied. The resistance percentage of the isolates to imipenem and meropenem antibiotics were 29.8% and 70.2%, respectively. Although all isolates were susceptible to colistin and polymyxin B, 78.9% of isolates had bla<sub>OXA-23</sub>, 8.8% bla<sub>OXA-24</sub>, and 1.7% bla<sub>OXA-58</sub> genes.

**Conclusion:** This study showed that beta-lactamase OXA-23 gene is the common identified known carbapenemase among carbapenem-resistant *A. baumannii* in Bandar Abbas Hospital. Evaluation of antibiotic-resistant genes in *A. baumannii* is necessary to further control dissemination of antibiotic resistance genes.

**Key words:** *Acinetobacter baumannii* – Carbapenemase – OXA-58 beta-lactmase

**Citation:** Najar Peerayeh S, Karmostaji A, Ansari M, Javadpour S, Davoodian P, Moradi N, Vahdani M. Molecular epidemiology of carbapenem resistance in *Acinetobacter baumannii* isolates in Shahid Mohammadi Hospital, Bandar Abbas, Iran. Hormozgan Medical Journal 2015;19(1):16-24.

## Introduction:

*Acinetobacter* is a Gram-negative, obligate aerobe, non-motile, oxidase-negative, non-fermenting, indole-negative, catalase-positive, and hemolytic bacterium which can use a variety of food sources (1). Laboratory methods based on biochemical and phenotypic properties can identify the genus of *Acinetobacter*; however, they cannot differentiate its various species. The most common type of nosocomial infections are caused by *A. baumannii*, *A. calcoaceticus*, *A. nosocomialis*, and genomic species 3. Bouvet and Grimut (1986) proposed 28 phenotypic tests for determination of the species (2); however, they were not able to differentiate the two species of *A. baumannii* and *A. nosocomialis* frequently isolated from clinical samples. As a result, the molecular methods of bla<sub>OXA-51</sub> gene identification were used to identify the dominant species in nosocomial infections, i.e. *A. baumannii* (1,3,4).

According to the Centers for Disease Control (CDC) in USA in 2004, *A. baumannii* was the cause of about 80% of *Acinetobacter* infections. The ability to acquire resistance by this bacterium has seriously endangered antibiotic therapy, especially in recent years (5). Although nosocomial pneumonia is the most common infection caused by the microorganism, infections of nervous system, skin, soft tissue, and bone have also been reported in some hospitals. This bacterium is the cause of more than 1% of nosocomial infections which mostly occur in patients in ICU and burn unit, immunocompromised patients, and those with underground diseases such as diabetes and chronic lung disease (6). The most important problem threatening the health system and hospitals about this bacterium is the occurrence of multi-drug resistant strains. *Acinetobacter* resistant to three or more antibiotics or resistant to a key antibiotic is known as multi-drug resistant bacteria (7). The bacterium is resistant to most commonly used antibiotics for treating infections such as aminoglycosides, quinolones, and broad spectrum beta-lactamases. Carbapenems are the treatment of choice for infections caused by this bacterium. The most important mechanism of resistance of *A. baumannii* against beta-lactam antibiotics is the production of beta-lactams, coded in the bacterial chromosome or plasmid, which are categorized as

Class D in the Ambler classification and are known as oxacillinases (8). Oxacillinases exert carbapenem hydrolyzing activity in *Acinetobacter* species and can hydrolyze imipenem and meropenem, and are classified in the 2df group in a new published classification (2010) (9). Five phylogenetic subtypes of beta-lactamases Class D have been identified so far in *A. baumannii* including the bla<sub>OXA-51/69</sub> groups and four branches of acquired enzymes including bla<sub>OXA-23</sub>, bla<sub>OXA-24/40</sub>, bla<sub>OXA-58</sub>, and bla<sub>OXA-143</sub>, each one possessing various enzymes with different sequences. Oxacillinase bla<sub>OXA-51</sub> naturally occurs merely in *A. baumannii* (10) and weakly hydrolyzes only the beta-lactam substrate of penicillin and carbapenem (11), unless additional elements of ISAbal or ISAb9 located at Bla<sub>OXA-51-like</sub> genes upstream enhance the expression of these genes (12). Over 68 varieties of different sequences of bla<sub>OXA-51</sub> have been categorized as Class D enzymes (13). Bla<sub>OXA-23</sub> enzyme is the first reported (1993) oxacillinase with carbapenemase activity which was initially called ARI-1 and was detected in *A. baumannii* plasmid in Scotland (14). Then, bla<sub>OXA-23</sub> gene was identified on chromosome and plasmid throughout the world; it was apparently unique to the genus *Acinetobacter*. One exception was reported in a *Proteus mirabilis* isolate in France (15). The second group of Class D enzymes was named bla<sub>OXA-24/40</sub> which was isolated from carbapenem resistant *A. baumannii* isolates in Spain (16). The third group of Class D carbapenemases detected in *A. baumannii* is characterized with bla<sub>OXA-58</sub> (17). Bla<sub>OXA-58</sub> gene has only been found so far in *Acinetobacter* species, including *A. junii* in Romania and Australia (18,19) and *A. nosocomialis* in Taiwan (2010) (20). Bla<sub>OXA-58</sub> is often a plasmid gene and most likely is responsible for its worldwide distribution. This gene is common in Italy and Greece (21,22). Carbapenem-resistant, bla<sub>OXA-58</sub>-producing *A. baumannii* species were responsible for several occurrences in neonatal intensive care units (23,24). Since updating information about changes in patterns of antibiotic resistance will improve experimental treatment in local hospitals, this study was carried out to detect the species of *A. baumannii* and to identify carbapenem-resistant strains and carbapenemase oxacillinase genes in *A. baumannii*.

## Methods:

A total of 69 *Acinetobacter* isolates were collected from Shahid Mohammadi Hospital of Bandar Abbas for this descriptive, cross-sectional study from October 2010 to March 2011. The bacteria were isolated from clinical specimens such as wounds, sputum, endotracheal aspirates, urine, blood, cerebrospinal fluid, and other body secretions.

An overnight culture in Mueller Hinton agar medium was prepared for each isolate. Gram staining was performed in order to see the Gram variable coccobacilli. To identify the genus of *Acinetobacter*, different biochemical tests were performed including oxidase (negative), indole (negative), motility in the SIM medium (negative), sugars fermentation in TSI (negative), growth at 42 °C, and melting the gelatin (25).

After identification, the *Acinetobacter* isolates were cultured in trypticase soy broth containing 15% glycerol, and stored at -70 °C on glass pearls.

To extract DNA, about six colonies of 24-hour grown bacteria were transferred into 1.5 mL Eppendorf tubes containing 200 µL TE buffer and vortexed to obtain a uniform suspension. These samples were then centrifuged at 8000 rpm for 8 min and the supernatant was discarded; 200 µL distilled water was added to the sample and mixed, homogenized, and centrifuged in the same way. The bacterial suspension was then placed 10 min in a boiling water bath and 10 min on ice. Freezing and thawing process was repeated 2 times. The suspension was centrifuged at 8000 rpm for 4 min and the supernatant was aliquoted in 0.5 mL sterile Eppendorf tubes and stored at -20 °C until PCR (26).

Primers used to identify genes *bla<sub>OXA-58</sub>*, *bla<sub>OXA-24</sub>*, *bla<sub>OXA-23</sub>*, and *bla<sub>OXA-51</sub>* are shown in Table 1 (27).

**Table 1. Primers used to identify genes *bla<sub>OXA-58</sub>*, *bla<sub>OXA-24</sub>*, *bla<sub>OXA-23</sub>*, and *bla<sub>OXA-51</sub>***

Gene	Nucleotide sequence	Amplicon size (bp)
<i>bla<sub>OXA-23</sub>-F</i>	GAT CGG ATT GGA GAA CCA GA	501
<i>bla<sub>OXA-23</sub>-R</i>	ATT TCT GAC CGC ATT TCC AT	
<i>bla<sub>OXA-24</sub>-F</i>	GGT TAG TTG GCC CCC TTA AA	246
<i>bla<sub>OXA-24</sub>-R</i>	AGT TGA GCG AAA AGG GGA TT	
<i>bla<sub>OXA-58</sub>-F</i>	AAG TAT TGG GGC TTG TGC TG	599
<i>bla<sub>OXA-58</sub>-R</i>	CCC CTC TGC GCT CTA CAT AC	
<i>bla<sub>OXA-51</sub>-F</i>	TAA TGC TTT GAT CGG CCT TG	353
<i>bla<sub>OXA-51</sub>-R</i>	TGG ATT GCA CTT CAT CTT GG	

Multiplex PCR was performed for oxacillinase genes according to the method described by Woodford et al. (27), at annealing temperature of 53 °C for one min.

The susceptibility of bacteria to antibiotics was evaluated through the disk diffusion method. Since the US Food and Drug Administration (FDA) has not provided a standard as a cutoff for sensitivity and resistance of *A. baumannii* to tigecycline, the standards proposed for the *Enterobacteriaceae* by FDA were used for interpreting the resistance to this antibiotic; i.e. an inhibition zone of equal to or greater than 19 mm as sensitive, 15-18 mm as

intermediate resistance, and equal to or less than 14 mm as resistant (28).


Antibiotic discs containing imipenem (IPM, 10 µg), meropenem (MEN, 10 µg), gentamicin (GM, 10µg), ciprofloxacin (CIP, 5µg), amikacin (AN, 30µg), cotrimoxazole (SXT, 25µg), cefepime (CPM, 30µg), cefotaxime (CTX, 30µg), aztreonam (ATM, 30µg), ceftazidime (CAZ, 30µg), polymixin B (PB, 300 U), tigecycline (TIG, 15µg), and colistin (CO, 10µg) were purchased from MAST Company. The standard strain of *E. coli*, ATCC25922 was used as a quality control disc.

The data were statistically analyzed through the chi-square test using SPSS 17, and the graphs were plotted using Excel.

## Results:

Out of 69 *Acinetobacter* isolates, 57 (82.6%) had bla<sub>OXA-51</sub> gene and were identified as *A. baumannii*; 35 isolates were from patients in ICU, 3 from emergency department, 12 from internal, 2 from neurology, 4 from general surgery, and 1 from neurosurgery wards; 25 isolates were from patients' trachea, 11 from burn wounds, 8 from surgical wounds, 7 from sputum, and 6 from urine; 45 isolates of *A. baumannii* (78.9%) had bla<sub>OXA-23</sub>, 5 (8.8%) bla<sub>OXA-24</sub>, and one (1.7%) bla<sub>OXA-58</sub> genes. Figure 1 depicts multiplex PCR reactions for genes bla<sub>OXA-51</sub>, bla<sub>OXA-24</sub>, bla<sub>OXA-58</sub>, and bla<sub>OXA-23</sub>.


Figure 1: Multiplex PCR reaction for the genes bla<sub>OXA-51</sub>, bla<sub>OXA-24</sub>, bla<sub>OXA-58</sub>, and bla<sub>OXA-23</sub>. Wells 1 and 6: bla<sub>OXA-51</sub> (353 bp) and bla<sub>OXA-24</sub> (246 bp); wells 2-4: bla<sub>OXA-51</sub> (353 bp) and bla<sub>OXA-23</sub> (501 bp); well 5: bla<sub>OXA-51</sub> (353 bp), bla<sub>OXA-23</sub> (501 bp), and bla<sub>OXA-58</sub> (599 bp); well 7: 100 bp ladder.



**Figure 1. Multiplex PCR reaction for the genes bla<sub>OXA-51</sub>, bla<sub>OXA-24</sub>, bla<sub>OXA-58</sub>, and bla<sub>OXA-23</sub>. Wells 1 and 6: bla<sub>OXA-51</sub> (353 bp) and bla<sub>OXA-24</sub> (246 bp); wells 2-4: bla<sub>OXA-51</sub> (353 bp) and bla<sub>OXA-23</sub> (501 bp); well 5: bla<sub>OXA-51</sub> (353 bp), bla<sub>OXA-23</sub> (501 bp), and bla<sub>OXA-58</sub> (599 bp); well 7: 100 bp ladder**

The resistance level of *A. baumannii* to antibiotics used in this study is shown in Diagram 1. As can be seen, no resistance was found in the case of colistin and polymyxin and the resistance percentage of these isolates to imipenem and meropenem antibiotics was 17 (29.8%) and 40 (70.2%), respectively. All 17 imipenem-resistant isolates carried bla<sub>OXA-23</sub> gene. In one imipenem-resistant isolate, two bla<sub>OXA-23</sub> and bla<sub>OXA-24</sub> genes

existed simultaneously, while the two genes bla<sub>OXA-23</sub> and bla<sub>OXA-58</sub> existed simultaneously in none of the imipenem-resistant isolates. From a total of 40 meropenem-resistant isolates, 39 (97.5%) carried bla<sub>OXA-23</sub>, 3 (7.5%) had bla<sub>OXA-23</sub> and bla<sub>OXA-24</sub> genes simultaneously, and one (2.5%) simultaneously carried three genes of bla<sub>OXA-23</sub>, bla<sub>OXA-24</sub>, and bla<sub>OXA-58</sub>. In one isolate, despite of resistance to meropenem, none of the oxacillinase genes were isolated, except for bla<sub>OXA-51</sub> which is specific for *A. baumannii*. In 17 isolates that were resistant both to imipenem and meropenem, 16 isolates (94.1%) contained only bla<sub>OXA-23</sub> and lack other carbapenemase genes.



**Diagram 1. The Pattern of Antibiotic Resistance of *A. baumannii* to Antibiotics Used in This Study**

## Conclusion:

Over the past decade, *Acinetobacter baumannii* has been known as the most successful pathogenic bacterium in hospitals throughout the world. Although there is a lot of information about the mechanisms of antibiotic resistance in this microorganism, it is still unstoppable, and today strains with global resistance, even resistant to colistin have been emerged which has seriously limited the treatment. Therefore, it seems necessary to focus on new therapies and to investigate on drugs that not only affect bacterial growth but also interfere with virulence indicators of the bacteria (4). As mentioned, the phenotypic methods are not able to identify the species of *A. baumannii*. Isolation of Bla<sub>OXA-51</sub> gene is a simple and reliable method for differentiation of *A. baumannii* from other species of *Acinetobacter* (10,30,31). Turton (2006) identified 106 isolates (62.3%) of *A. baumannii* out of 170 isolates of *Acinetobacter* via

ARDRA method; all these isolates had bla<sub>oxa-51</sub> gene (10). Different frequencies were reported throughout the world for *A. baumannii* identified through bla<sub>oxa-51</sub> gene, for example, 84.37% in Iran in 2008 (32), 77.8% in Turkey in 2006 (33), and 91.30% in Taiwan (34) and 89.41% in the UK in 2006 (27). The rate of isolation of this microorganism in our study was 82.6%, which is similar to studies in Iran and closer to the rest of the world. Various reports from around the world indicate an increased occurrence of resistance to carbapenem in *A. baumannii*. Several outbreaks of carbapenem-resistant *A. baumannii* have been reported from hospitals in Northern Europe such as Spain, Portugal, France, England, and Ireland, as well as Czech Republic, Poland, Eastern Europe, and Middle East. This rate was 8% in Bulgaria in 2003 but has increased to 52-74% in 2005-2006 (35,36). In Iran, the rate of resistance was reported 49.3% to imipenem and 50% resistance to meropenem in 2008 (32), 52.5% to imipenem and meropenem in 2009 (37), and 49.26% to imipenem in 2011 (38); these are more than the resistance to imipenem observed in this study (29.8%), however, the resistance of strains to meropenem in our study was higher than other Iranian studies (70.2%). Carbapenem-resistant strains with varying degrees of prevalence have been reported from other parts of the world such as Spain, Belgium, Brazil, Cuba, Britain, France, Hong Kong, Kuwait, Singapore, and Argentina (39). In Madagascar, 44% of *A. baumannii* isolated from 5 hospitals during 2006-2009 were carbapenem-resistant (40). In a study in 2006 in Turkey, 26.6% and 7.1% of *Acinetobacter* strains isolated from seven treatment centers were resistant to imipenem and meropenem, respectively (33). Different studies have shown wide dissemination of carbapenem-resistant species carrying oxacillinase genes throughout the world, although significant geographic differences were observed in the molecular epidemiology of Class D carbapenemase or oxacillinase genes. In all studies, same as our research, bla<sub>oxa-23</sub> gene was highly prevalent among strains resistant to carbapenem. Mendoz et al. found Class D carbapenemase genes in 70% of strains isolated from 41 medical centers in 10 countries during 2006 to 2007; bla<sub>oxa-23-like</sub> gene was more common and included 95% of genes

encoding Class D carbapenemase; and the next genes were bla<sub>oxa-58</sub> (11.9%) and bla<sub>oxa-24/40</sub> (5.6%) (41,44). In 2009 in the United States, 13% of imipenem-resistant isolates carried bla<sub>oxa-23</sub>, and no other carbapenemase genes such as bla<sub>oxa-24</sub> and bla<sub>oxa-58</sub> were found (42). In Bulgaria, 72.7% and 27.27% of carbapenem-resistant isolates had bla<sub>oxa-23-like</sub> and bla<sub>oxa-58-like</sub> genes, respectively (36). In 2008 in Texas, 11 strains out of 13 carbapenem-resistant strains carried oxacillinase-coding genes, and 6 isolates had bla<sub>oxa-24</sub> and 5 had bla<sub>oxa-58</sub> genes; all strains carried bla<sub>oxa-51</sub> gene which is the gene encoding the constitutive enzyme characteristic of *A. baumannii* (43). In a study in Madagascar during 2006 to 2009, bla<sub>oxa-23</sub> and bla<sub>oxa-51</sub> genes were found in all strains of the 44% of carbapenem-resistant isolates of *A. baumannii*, but bla<sub>oxa-24</sub> and bla<sub>oxa-58</sub> were absent (40). In our study, despite resistance to meropenem, one strain lacked all oxacillinase genes except bla<sub>oxa-51</sub> indicating the role of other factors is the resistance which was not addressed in this study. Tigecycline is the antibiotic of choice for treatment of carbapenem-resistant strains, and our study showed that 6 samples (10.5%) of carbapenem-resistant strains were also resistant to tigecycline. Thus, we suggest using this antibiotic for treatment of carbapenem-resistant strains, of course after performing antibiogram test. Out of 17 strains resistant to imipenem and meropenem, 16 isolates (94.1%) carried only bla<sub>oxa-23</sub> gene. Therefore, resistance to carbapenems can be attributed to the high prevalence of this carbapenemase among the isolates.

The high prevalence of bla<sub>oxa-23</sub> gene among carbapenem-resistant strains is a warning about the potential distribution of clones carrying this gene in hospital environment. Therefore, conducting extensive epidemiological studies can help increase our knowledge about the epidemiology of this microorganism and its potential transmission paths in hospital environment. The isolates of *Acinetobacter baumannii* in the studied hospital revealed high resistance to commonly used antibiotics and only polymyxin B and colistin are recognized as effective drugs in the treatment of infections caused by this bacterium. Information on changes in resistance patterns of this microorganism in local hospitals can help improve the experimental

treatment in hospitals and the proper management for correct selection of antimicrobial agents.

## References:

1. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev*. 2008;21:538-582.
2. Bouvet PJM, Grimont PAD. Taxonomy of the Genus *Acinetobacter* with the Recognition of *Acinetobacter baumannii* sp. nov. *Acinetobacter haemolyticus* sp. nov. *Acinetobacter johnsonii* sp. nov. and *Acinetobacter junii* sp. nov. and Emended Descriptions of *Acinetobacter calcoaceticus* and *Acinetobacter Iwoffii*. *International Journal of Systematic and Evolutionary Microbiology*. 1986;2:228-240.
3. Hauck Y, Soler C, Jault P, Merens A, Gerome P, Nab CM. Diversity of *Acinetobacter baumannii* in four French military hospitals, as assessed by multiple locus variable number of tandem repeats analysis. *PLoS One*. 2012;7:1-9.
4. Roca I, Espinal P, Vila-Farres X, Vila J. The *Acinetobacter baumannii* Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. *Front Microbiol*. 2012;3:148.
5. Espinal P, Marti S, Vila J. Effect of biofilm formation on the survival of *Acinetobacter baumannii* on dry surfaces. *J Hosp Infect*. 2012;80:56-60.
6. Camp C, Tatum O. A Review of *Acinetobacter baumannii* as a Highly Successful Pathogen in Times of War. *Lab Med*. 2010;41:649-657.
7. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18:268-681.
8. Opazo A, Dominguez M, Bello H, Amyes SG, Gonzalez-Rocha G. OXA-type carbapenemases in *Acinetobacter baumannii* in South America. *J Infect Dev Ctries*. 2012;6:311-316.
9. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother*. 2010;54:969-976.
10. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol*. 2006;44:2974-2976.
11. Héritier C, Poirel L, Fournier PE, Clavierie JM, Raoult D, Nordmann P. Characterization of the naturally occurring oxacillinase of *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2005;49:4174-4179.
12. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of ISAba1 in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS Microbiol Lett*. 2006;258:72-77.
13. Zhao WH, Hu ZQ. *Acinetobacter*: a potential reservoir and dispenser for beta-lactamases. *Crit Rev Microbiol*. 2012;38:30-51.
14. Paton R, Miles RS, Hood J, Amyes SG, Miles RS, Amies SG. ARI 1: beta-lactamase-mediated imipenem resistance in *Acinetobacter baumannii*. *Int J Antimicrob Agents*. 1993;2:81-87.
15. Bonnet R, Marchandin H, Chanal C, Sirot D, Labia R, De Champs C, et al. Chromosome encoded class D beta-lactamase OXA-23 in *Proteus mirabilis*. *Antimicrob Agents Chemother*. 2002;46:2004-2006.
16. Bou G, Oliver A, Martinez-Beltrán J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an *Acinetobacter baumannii* clinical strain. *Antimicrob Agents Chemother*. 2000;44:1556-1561.
17. Poirel L, Marque S, Héritier C, Segonds C, Chabanon G, Nordmann P. OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2005;49:202-208.
18. Marque S, Poirel L, Héritier C, Brisse S, Blasco MD, Filip R et al. Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in *Acinetobacter* spp. in Europe. *J Clin Microbiol*. 2005;43:4885-4888.
19. Peleg AY, Franklin C, Walters LJ, Bell JM, Spelman DW. OXA-58 and IMP-4 carbapenem-hydrolyzing beta-lactamases in an *Acinetobacter junii* blood culture isolate from Australia. *Antimicrob Agents Chemother*. 2006;50:399-400.
20. Lin YC, Hsia KC, Chen YC, Sheng WH, Chang SC, Liao MH, et al. Genetic basis of multidrug resistance in *Acinetobacter* clinical isolates in Taiwan. *Antimicrob Agents Chemother*. 2010;54:2078-2084.

21. D'Arezzo S, Capone A, Petrosillo N, Visca P, Ballardini M, Bartolini S, et al. Epidemic multidrug-resistant *Acinetobacter baumannii* related to European clonal types I and II in Rome (Italy). *Clin Microbiol Infect.* 2009;15:347-357.
22. Papa A, Koulourida V, Souliou E. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* in a newly established Greek hospital. *Microb Drug Resist.* 2009;15:257-260.
23. Poirel L, Lebessi E, Heritier C, Patsoura A, Foustoukou M, Nordmann P. Nosocomial spread of OXA-58-positive carbapenem-resistant *Acinetobacter baumannii* isolates in a paediatric hospital in Greece. *Clin Microbiol Infect.* 2006;12:1138-1141.
24. Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, Bethimouti K, Maniatis AN. Outbreak of multiple clones of imipenem-resistant *Acinetobacter baumannii* isolates expressing OXA-58 carbapenemase in an intensive care unit. *J Antimicrob Chemother.* 2006;57:557-561.
25. Murray PR. Manual of clinical microbiology. Philadelphia: Mosby Press; 2003:749-752.
26. Andriamanantena TS, Ratsima E, Rakotonirina HC, Randrianirina F, Ramparany L, Carod JF. Dissemination of multidrug resistant *Acinetobacter baumannii* in various hospitals of Antananarivo Madagascar. *Ann Clin Microbiol Antimicrob.* 2010;9:2-6.
27. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents.* 2006;27:351-353.
28. Wikler MA. Performance standards for antimicrobial susceptibility testing: Mosby Press; 2006.
29. Tan TY, Ng LS, Poh K. Susceptibility testing of unconventional anti-biotics against multiresistant *Acinetobacter* spp. by agar dilution and Vitek 2. *Diagn Microbiol Infect Dis.* 2007;58:357-361.
30. Andrea KM, Daniela C. bla(OXA-51)-type  $\beta$ -lactamase genes are ubiquitous and vary within a strain in *Acinetobacter baumannii*. *Int J Antimicrob Agents.* 2006;28:110-113.
31. Hu WS, Yao SM, Fung CP, Hsieh YP, Liu CP, Lin SF. OXA-66/OXA-51-Like Carbapenemase and Possibly an Efflux Pump Are Associated with Resistance to Imipenem in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2007;51:3844-3852.
32. Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among *Acinetobacter* spp. Isolated from patients at Tehran hospitals. *Jpn J Infect Dis.* 2008;61:274-278.
33. Vahaboglu H, Budak F, Kasap M, Gacar G, Torol S, Karadenizli A. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of *Acinetobacter* spp.: co-existence with OXA-58 in multiple centres. *J Antimicrob Chemother.* 2006;58:537-542.
34. Lee YT, Fung CP, Wang FD, Chen CP, Chen TL, Cho WL. Outbreak of imipenem-resistant *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex harboring different carbapenemase gene-associated genetic structures in an intensive care unit. *J Microbiol Immunol Infect.* 2012;45:43-51.
35. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in *Acinetobacter baumannii*: the molecular epidemic features of an emerging problem in health care facilities. *J Infect Dev Ctries.* 2009;3:335-341.
36. Stoeva T, Higgins PG, Savov E, Markovska R, Mitov I, Seifert H. Nosocomial spread of OXA-23 and OXA-58 beta-lactamase-producing *Acinetobacter baumannii* in a Bulgarian hospital. *J Antimicrob Chemother.* 2009;63:618-620.
37. Taherikalani M, Fatollahzadeh B, Emaneini M, Soroush S, Feizabadi MM. Distribution of different carbapenem resistant clones of *Acinetobacter baumannii* in Tehran hospitals. *New Microbiol.* 2009;32:265-271.
38. Shahcheraghi F, Abbasalipour M, Feizabadi M, Ebrahimipour G, Akbari N. Isolation and genetic characterization of metallo-beta-lactamase and carbapenemase producing strains of *Acinetobacter baumannii* from patients at Tehran hospitals. *Iran J Microbiol.* 2011;3:68-74.
39. Corbella X, Montero A, Pujol M, Dominguez MA, Ayats J, Argerich MJ. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant *Acinetobacter baumannii*. *J Clin Microbiol.* 2000;38:4086-4095.
40. Andriamanantena TS, Ratsima E, Rakotonirina HC, Randrianirina F, Ramparany L, Carod JF.

- Dissemination of multidrug resistant *Acinetobacter baumannii* in various hospitals of Antananarivo Madagascar. *Ann Clin Microbiol Antimicrob.* 2010;9:2-6.
41. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among *Acinetobacter* spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. *J Antimicrob Chemother.* 2009;63:55-59.
42. Srinivasan VB, Rajamohan G, Pancholi P, Stevenson K, Tadesse D, Patchanee P. Genetic relatedness and molecular characterization of multidrug resistant *Acinetobacter baumannii* isolated in central Ohio, USA. *Ann Clin Microbiol Antimicrob.* 2009;8:1-10.
43. Castanheira M, Wanger A, Kruzal M, Deshpande LM, Jones RN. Emergence and clonal dissemination of OXA-24- and OXA-58-producing *Acinetobacter baumannii* strains in Houston, Texas: report from the SENTRY Antimicrobial Surveillance Program. *J Clin Microbiol.* 2008;46:3179-3180.
42. Srinivasan VB, Rajamohan G, Pancholi P, Stevenson K, Tadesse D, Patchanee P. Genetic



# اپیدمیولوژی مولکولی مقاومت به کرباپنم در ایزوله‌های استیتوباکتر بامانی بیمارستان شهید محمدی بندرعباس

شهین نجار پیرایه<sup>۱</sup> افسانه کرمستجی<sup>۲</sup> مریم انصاری<sup>۳</sup> صدیقه جوادیپور<sup>۴</sup> پریش داودیان<sup>۵</sup> ناهید مرادی<sup>۶</sup> مهشید وحدانی<sup>۳</sup>  
<sup>۱</sup> دانشیار، گروه باکتری‌شناسی پزشکی، دانشگاه تربیت مدرس، تهران، ایران. <sup>۲</sup> استادیار، گروه باکتری‌شناسی پزشکی، <sup>۳</sup> کارشناس ارشد، بیولوژی مولکولی، <sup>۴</sup> دانشیار، گروه باکتری‌شناسی پزشکی، <sup>۵</sup> استادیار، گروه عفونی، <sup>۶</sup> کارشناس ارشد، باکتری‌شناسی، مرکز تحقیقات بیماریهای عفونی و گرمسیری، دانشگاه علوم پزشکی هرمزگان، بندرعباس، ایران.

مجله پزشکی هرمزگان سال نوزدهم شماره اول ۹۴ صفحات ۲۴-۱۶

## چکیده

**مقدمه:** استیتوباکتر بامانی عامل مهم عفونت‌های بیمارستانی است که بیشتر بیماران ناتوان در بخش‌های مراقبت‌های ویژه را درگیر می‌سازد. این باکتری، با توانایی کسب شاخص‌های مقاومت، درمان‌های آنتی‌بیوتیکی را با تهدید جدی مواجه ساخته است. مهم‌ترین مشکل پیش روی درمان در این باکتری، گزارشات روزافزون از مقاومت به طیف وسیعی از آنتی‌بیوتیک‌ها، از جمله کرباپنم‌ها است که درمان انتخابی عفونت‌های این باکتری می‌باشد، یکی از عوامل اصلی مقاومت به کرباپنم‌ها، اگزاسیلینازهای متعلق به گروه D بتالاکتامازها (OXA-type) هستند. مطالعه حاضر به منظور بررسی الگوی مقاومت آنتی‌بیوتیکی و شیوع ژن‌های کرباپنمازی اگزاسیلینازها در ایزوله‌های بالینی استیتوباکتر بامانی در بیمارستان بندرعباس، ایران طراحی شد.

**روش کار:** تعداد ۶۹ ایزوله استیتوباکتر، در طی دو سال از بیمارستان شهید محمدی شهر بندرعباس از نمونه‌های مختلف بدن بیماران جمع‌آوری شد. این ایزوله‌ها با استفاده از روش‌های بیوشیمیایی تا حد جنس و با تکنیک PCR گونه استیتوباکتر بامانی شناسایی شد. الگوی مقاومت آنتی‌بیوتیکی برای ایمپنم و مروپنم به روش دیسک دیفیوژن انجام شد. ژن‌های مقاومت به کرباپنم‌ها، OXA-type به روش multiplex PCR شناسایی شد. تجزیه و تحلیل آماری با استفاده از آزمون آماری کای اسکور و نرم افزار SPSS 17 و جهت رسم نمودارها از نرم افزار Excell استفاده شد.

**نتایج:** از ۶۹ استیتوباکتر، ۵۷ ایزوله (۸۲/۶٪) دارای ژن bla OXA-51 بودند که به عنوان استیتوباکتر بامانی شناسایی شدند. بررسی آنتی‌بیوگرام مقاومت بالایی رابه آنتی‌بیوتیک‌های بتالاکتام و سایر آنتی‌بیوتیک‌های مورد مطالعه نشان داد. درصد مقاومت این ایزوله‌ها به آنتی‌بیوتیک‌های ایمپنم و مروپنم به ترتیب ۲۹/۸٪ و ۷۰/۲٪ بود. اگرچه همه ایزوله‌ها به کلی سنتین و پلی میکسین بی حساس بودند، ۷۸/۹٪ از ایزوله‌ها دارای ژن bla oxa-23، ۱/۸٪ حاوی ژن bla OXA-24 و ۱/۷٪ حامل ژن bla OXA-58 بودند.

**نتیجه‌گیری:** مطالعه حاضر نشان داد که ژن بتالاکتاماز OXA-23 شایع کرباپنماز شناسایی شده در میان استیتوباکتر بامانی مقاوم به کرباپنم‌ها در بیمارستان بندرعباس است. ارزیابی ژن‌های مقاوم به آنتی‌بیوتیک‌ها در استیتوباکتر بامانی جهت کنترل انتشار بیشتر ژن‌های مقاومت آنتی‌بیوتیکی ضروری است.

**کلیدواژه‌ها:** استیتوباکتر بامانی - کرباپنماز - بتالاکتاماز bla OXA-58

نویسنده مسئول:  
 دکتر افسانه کرمستجی  
 مرکز تحقیقات بیماریهای عفونی و  
 گرمسیری دانشگاه علوم پزشکی  
 هرمزگان  
 بندرعباس - ایران  
 تلفن: ۶۶۶۶۳۶۵ ۰۹۸ ۷۶  
 پست الکترونیکی:  
 afsanehkk@yahoo.com

نوع مقاله: پژوهشی

دریافت مقاله: ۹۲/۱۰/۱ اصلاح نهایی: ۹۳/۲/۲۰ پذیرش مقاله: ۹۳/۲/۲۸

ارجاع: نجار پیرایه شهین، کرمستجی افسانه، انصاری مریم، جوادیپور صدیقه، داودیان پریش، مرادی ناهید، وحدانی مهشید. اپیدمیولوژی مولکولی مقاومت به کرباپنم در ایزوله‌های استیتوباکتر بامانی بیمارستان شهید محمدی بندرعباس. مجله پزشکی هرمزگان ۱۳۹۴؛(۱):۲۴-۱۶.